{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:28:16Z","timestamp":1792193296971,"version":"4.4.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T00:00:00Z","timestamp":1640044800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.eururo.2021.12.007","type":"journal-article","created":{"date-parts":[[2021,12,31]],"date-time":"2021-12-31T07:31:26Z","timestamp":1640935886000},"page":"337-346","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":98,"title":["Systematic Review of Active Surveillance for Clinically Localised Prostate Cancer to Develop Recommendations Regarding Inclusion of Intermediate-risk Disease, Biopsy Characteristics at Inclusion and Monitoring, and Surveillance Repeat Biopsy Strategy"],"prefix":"10.1016","volume":"81","author":[{"given":"Peter-Paul M.","family":"Willemse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niall F.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Grivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Zattoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Lardas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Briers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus G.","family":"Cumberbatch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"De Santis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Dell'Oglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James F.","family":"Donaldson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Fossati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Gandaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Gillessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy P.","family":"Grummet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann M.","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Liew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"MacLennan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malcolm D.","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Moris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Plass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shane","family":"O'Hanlon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Imran","family":"Omar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela E.","family":"Oprea-Lager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl H.","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine C.","family":"Paterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Ploussard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Rouvi\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivo G.","family":"Schoots","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derya","family":"Tilki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roderick C.N.","family":"van den Bergh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Van den Broeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodorus H.","family":"van der Kwast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henk G.","family":"van der Poel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Wiegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathy Yuhong","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Cornford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Mottet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas B.L.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2021.12.007_b0005","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.1200\/JCO.2015.62.5764","article-title":"Intermediate and longer-term outcomes from a prospective active-surveillance program for favorable-risk prostate cancer","volume":"33","author":"Tosoian","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2021.12.007_b0010","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/MOU.0b013e328352598c","article-title":"Active surveillance: the Canadian experience","volume":"22","author":"Klotz","year":"2012","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.eururo.2021.12.007_b0015","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.eururo.2012.11.005","article-title":"Active surveillance for low-risk prostate cancer worldwide: the PRIAS study","volume":"63","author":"Bul","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2021.12.007_b0020","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1200\/JCO.2010.32.8112","article-title":"Active surveillance program for prostate cancer: an update of the Johns Hopkins experience","volume":"29","author":"Tosoian","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2021.12.007_b0025","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.eururo.2019.09.020","article-title":"EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel consensus statements for deferred treatment with curative intent for localised prostate cancer from an international collaborative study (DETECTIVE study)","volume":"76","author":"Lam","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2021.12.007_b0030","article-title":"Systematic review of deferred treatment with curative intent for localised prostate cancer to explore heterogeneity of definitions, thresholds and criteria and clinical effectiveness","author":"Willemse","year":"2018","journal-title":"Prospero"},{"key":"10.1016\/j.eururo.2021.12.007_b0035","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.eururo.2021.12.007_b0040","doi-asserted-by":"crossref","first-page":"iii","DOI":"10.3310\/hta9020","article-title":"Do the findings of case series studies vary significantly according to methodological characteristics?","volume":"9","author":"Dalziel","year":"2005","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.eururo.2021.12.007_b0045","series-title":"Methods guide for effectiveness and comparative effectiveness reviews","article-title":"Assessing the risk of bias of individual studies in systematic reviews of health care interventions","author":"Viswanathan","year":"2012"},{"key":"10.1016\/j.eururo.2021.12.007_b0050","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.eururo.2015.11.023","article-title":"Role of hormonal treatment in prostate cancer patients with nonmetastatic disease recurrence after local curative treatment: a systematic review","volume":"69","author":"van den Bergh","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2021.12.007_b0055","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1200\/JCO.2014.55.1192","article-title":"Long-term follow-up of a large active surveillance cohort of patients with prostate cancer","volume":"33","author":"Klotz","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2021.12.007_b0060","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/bju.14935","article-title":"Active surveillance in intermediate-risk prostate cancer","volume":"125","author":"Klotz","year":"2020","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2021.12.007_b0065","doi-asserted-by":"crossref","first-page":"3992","DOI":"10.1002\/cncr.28303","article-title":"Development and multi-institutional validation of an upgrading risk tool for Gleason 6 prostate cancer","volume":"119","author":"Truong","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2021.12.007_b0070","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.euo.2018.03.015","article-title":"Active surveillance for prostate cancer in a real-life cohort: comparing outcomes for PRIAS-eligible and PRIAS-ineligible patients","volume":"1","author":"Soeterik","year":"2018","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2021.12.007_b0075","doi-asserted-by":"crossref","first-page":"238","DOI":"10.5489\/cuaj.4093","article-title":"An assessment of Prostate Cancer Research International: Active Surveillance (PRIAS) criteria for active surveillance of clinically low-risk prostate cancer patients","volume":"11","author":"da Silva","year":"2017","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.eururo.2021.12.007_b0080","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1200\/JCO.2010.33.0134","article-title":"Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance","volume":"29","author":"Porten","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2021.12.007_b0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/M17-0548","article-title":"Comparative analysis of biopsy upgrading in four prostate cancer active surveillance cohorts","volume":"168","author":"Inoue","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.eururo.2021.12.007_b0090","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.urolonc.2011.06.011","article-title":"Impact of immediate TRUS rebiopsy in a patient cohort considering active surveillance for favorable risk prostate cancer","volume":"31","author":"King","year":"2013","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2021.12.007_b0095","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/cncr.23575","article-title":"Role of repeated biopsy of the prostate in predicting disease progression in patients with prostate cancer on active surveillance","volume":"113","author":"Al Otaibi","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2021.12.007_b0100","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.ucl.2014.01.011","article-title":"Optimization of prostate biopsy: review of technique and complications","volume":"41","author":"Bjurlin","year":"2014","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.eururo.2021.12.007_b0105","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/bju.15065","article-title":"Prostate cancer upgrading with serial prostate magnetic resonance imaging and repeat biopsy in men on active surveillance: are confirmatory biopsies still necessary","volume":"126","author":"Osses","year":"2020","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2021.12.007_b0110","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.eururo.2021.05.001","article-title":"Reliability of serial prostate magnetic resonance imaging to detect prostate cancer progression during active surveillance: a systematic review and meta-analysis","volume":"80","author":"Rajwa","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2021.12.007_b0115","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.juro.2017.10.029","article-title":"Tumor volume on biopsy of low risk prostate cancer managed with active surveillance","volume":"199","author":"Tosoian","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2021.12.007_b0120","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.euf.2019.05.001","article-title":"Impact of tumor regional involvement on active surveillance outcomes: validation of the cumulative cancer location metric in a US population","volume":"6","author":"Leong","year":"2020","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2021.12.007_b0125","doi-asserted-by":"crossref","first-page":"464","DOI":"10.5301\/tj.5000649","article-title":"Eleven-year management of prostate cancer patients on active surveillance: what have we learned?","volume":"103","author":"Marenghi","year":"2017","journal-title":"Tumori"},{"key":"10.1016\/j.eururo.2021.12.007_b0130","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1007\/s00345-017-2047-z","article-title":"Population-based study of grade progression in patients who harboured Gleason 3 + 3","volume":"35","author":"Sampurno","year":"2017","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2021.12.007_b0135","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S0022-5347(05)67998-0","article-title":"The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy","volume":"163","author":"Sebo","year":"2000","journal-title":"J Urol"},{"issue":"3 Pt 1","key":"10.1016\/j.eururo.2021.12.007_b0140","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.juro.2007.05.038","article-title":"Predictors of histological disease progression in untreated, localized prostate cancer","volume":"178","author":"Venkitaraman","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2021.12.007_b0145","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1111\/j.1464-410X.2008.08116.x","article-title":"Prostate-specific antigen (PSA) kinetics in untreated, localized prostate cancer: PSA velocity vs PSA doubling time","volume":"103","author":"Ng","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2021.12.007_b0150","doi-asserted-by":"crossref","first-page":"83","DOI":"10.21037\/tau.2017.12.24","article-title":"Active surveillance for prostate cancer: a systematic review of contemporary worldwide practices","volume":"7","author":"Kinsella","year":"2018","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.eururo.2021.12.007_b0155","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/nrurol.2015.313","article-title":"Active surveillance for prostate cancer: a narrative review of clinical guidelines","volume":"13","author":"Bruinsma","year":"2016","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.eururo.2021.12.007_b0160","doi-asserted-by":"crossref","first-page":"243","DOI":"10.21037\/tau.2018.03.02","article-title":"Active surveillance review: contemporary selection criteria, follow-up, compliance and outcomes","volume":"7","author":"Komisarenko","year":"2018","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.eururo.2021.12.007_b0165","doi-asserted-by":"crossref","first-page":"e027860","DOI":"10.1136\/bmjopen-2018-027860","article-title":"PCASTt\/SPCG-17\u2014A randomised trial of active surveillance in prostate cancer: rationale and design","volume":"9","author":"Ahlberg","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.eururo.2021.12.007_b0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta24370","article-title":"Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT","volume":"24","author":"Hamdy","year":"2020","journal-title":"Health Technol Assess"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283821022156?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283821022156?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T13:11:51Z","timestamp":1759583511000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283821022156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S0302283821022156"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2021.12.007","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systematic Review of Active Surveillance for Clinically Localised Prostate Cancer to Develop Recommendations Regarding Inclusion of Intermediate-risk Disease, Biopsy Characteristics at Inclusion and Monitoring, and Surveillance Repeat Biopsy Strategy","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2021.12.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}